Verastem (VSTM) Reports Q4 Loss Per Share of 37c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. JNJ
3. AAPL
4. META
5. NVDA
6. AMAT
7. NRIX
8. SPY
9. OIG
10. BAC

Go back to Verastem (VSTM) Reports Q4 Loss Per Share of 37c

Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate Developments

March 12, 2019 4:08 PM EDT

U.S. Commercial Launch of COPIKTRA Underway

$1.7 Million in 2018 Net Product Revenues from COPIKTRA

Cash, Cash Equivalents and Short-Term Investments of $249.7 million as December 31, 2018

BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (Nasdaq: VSTM), operating as Verastem Oncology, (or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today reported financial results for the three and twelve months ended December 31, 2018, including revenue from its first commercial product, COPIKTRA (duvelisib), which was approved by the U.S. Food and Drug... More